Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
07:43

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics

Published on: May 3, 2024

4.2K

Decoding osteosarcoma from heterogeneity to precision therapy

Yu Xu1, Yanfu Bai2, Fan Yang2

  • 1Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Discover Oncology
|December 11, 2025
PubMed

Insights

Osteosarcoma (OS) molecular subtypes reveal unique drivers and therapeutic resistance patterns. Understanding these distinct profiles is key for developing targeted precision medicine strategies to improve patient survival.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Osteosarcoma (OS) is the most common bone cancer in adolescents, characterized by significant genetic and cellular diversity.
  • Current treatments offer limited survival benefits for metastatic or refractory OS due to this heterogeneity.

Purpose of the Study:

  • To review advances in molecular subtyping of Osteosarcoma.
  • To highlight subtype-specific drivers, their role in progression and resistance.
  • To explore potential precision medicine approaches based on molecular profiles.

Main Methods:

  • Integration of multi-omic data, including bulk and single-cell transcriptomics.
  • Application of spatial profiling, epigenetic mapping, and proteomic analyses.
  • Comprehensive literature review of recent Osteosarcoma research.

Main Results:

  • Identification of distinct molecular subtypes with unique genomic, epigenomic, transcriptomic, and tumor microenvironmental signatures.
  • Uncovered subtype-specific oncogenic drivers influencing OS pathogenesis.
  • Revealed insights into therapeutic resistance mechanisms linked to molecular profiles.

Conclusions:

  • Molecular subtyping provides a deeper understanding of Osteosarcoma heterogeneity.
  • Targeted therapies based on identified subtypes hold promise for improved treatment outcomes.
  • Precision medicine strategies tailored to molecular profiles are crucial for advancing OS care.
Keywords:
HeterogeneityMulti-omicsOsteosarcomaPrecision therapy

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.4K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K